Neflamapimod + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dementia With Lewy Bodies
Conditions
Dementia With Lewy Bodies
Trial Timeline
May 1, 2023 → Jun 16, 2025
NCT ID
NCT05869669About Neflamapimod + Placebo
Neflamapimod + Placebo is a phase 2 stage product being developed by CervoMed for Dementia With Lewy Bodies. The current trial status is completed. This product is registered under clinical trial identifier NCT05869669. Target conditions include Dementia With Lewy Bodies.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07033481 | Phase 2 | Recruiting |
| NCT06987643 | Phase 2 | Recruiting |
| NCT05869669 | Phase 2 | Completed |
Competing Products
20 competing products in Dementia With Lewy Bodies
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 3 | 69 |
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 69 |
| AL001 | Alector | Phase 2 | 44 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| IGC AD1 + Placebo | IGC Pharma | Phase 1 | 25 |
| E2020 + Placebo | Eisai | Approved | 85 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Rasagiline | Eisai | Phase 2 | 52 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 23 |
| donepezil hcl | Eisai | Phase 3 | 77 |
| Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo | Eisai | Phase 3 | 77 |
| E2020 + E2020 | Eisai | Phase 2 | 52 |
| donepezil hydrochloride (Aricept) | Eisai | Approved | 85 |
| 3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo | Eisai | Phase 2 | 52 |
| E2020 + E2020 | Eisai | Phase 3 | 77 |
| Irsenontrine + Placebo | Eisai | Phase 2 | 52 |
| E2020 | Eisai | Phase 2 | 52 |
| Mecobalamin | Eisai | Approved | 85 |
| E2020 + Placebo | Eisai | Phase 3 | 77 |
| Donepezil Hydrochloride | Eisai | Phase 3 | 77 |